Trials show conflicting heart failure data on gliptins in diabetes

Trial data showed DPP-4 inhibitors, or "gliptins," were associated with a slightly increased risk of heart failure in type 2 diabetes patients on metformin. However, another study showed patients starting on DPP-4 treatment did not have a higher risk of heart failure than patients starting other ...


This news summary appeared in DiabetesPro SmartBrief on 07/02/2014
Click here to view the full issue.

View the original article:
Medscape (free registration)

Want to see more news summaries?
Sign up for DiabetesPro SmartBrief

DiabetesPro SmartBrief is a FREE, daily email newsletter that summarizes the day's top industry news from hundreds of sources. Each day, subscribers receive 8-10 headlines and news summaries like the one to the left
Sign up:
About SmartBrief
SmartBrief is the leading online publisher of targeted business news and information by industry. By combining technology and editorial expertise, SmartBrief filters thousands of sources daily to deliver the most relevant industry news in partnership with more than 180 trade associations, professional societies nonprofits and corporate entities